- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Joe Fuhr, PhD, Discusses His Predictions for the Growing Biosimilar Market
We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.
The United States’ slow start to biosimilar uptake has manifested in a number of ways, from delayed launches due to patent disputes to anticompetitive practices creating a distrust of biosimilars among patients and physicians. However, some experts still see hope for the industry.
We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
